{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T18:59:34Z","timestamp":1766516374537,"version":"build-2065373602"},"reference-count":31,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","eu-focus.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Focus"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.euf.2019.02.020","type":"journal-article","created":{"date-parts":[[2019,3,8]],"date-time":"2019-03-08T17:27:55Z","timestamp":1552066075000},"page":"26-30","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Patient-reported Outcome Measures in Metastatic Urinary Cancers"],"prefix":"10.1016","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0037-0303","authenticated-orcid":false,"given":"Cristiane Decat","family":"Bergerot","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paulo Gustavo","family":"Bergerot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Errol J.","family":"Philip","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1712-0848","authenticated-orcid":false,"given":"Sumanta Kumar","family":"Pal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.euf.2019.02.020_bib0005","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.euf.2019.02.020_bib0010","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1200\/JCO.1993.11.3.570","article-title":"The functional assessment of cancer therapy scale: development and validation of the general measure","volume":"11","author":"Cella","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2019.02.020_bib0015","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1200\/JCO.2015.61.6706","article-title":"American Society of Clinical Oncology statement: a conceptual framework to assess the value of cancer treatment options","volume":"33","author":"Schnipper","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2019.02.020_bib0020","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1093\/annonc\/mdv249","article-title":"A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)","volume":"26","author":"Cherny","year":"2015","journal-title":"Ann Oncol"},{"year":"2013","series-title":"Delivering high-quality cancer care: charting a new course for a system in crisis","author":"Institute of Medicine","key":"10.1016\/j.euf.2019.02.020_bib0025"},{"key":"10.1016\/j.euf.2019.02.020_bib0030","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1001\/jama.2017.7156","article-title":"Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment","volume":"318","author":"Basch","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.euf.2019.02.020_bib0035","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1158\/1078-0432.CCR-15-2035","article-title":"Focusing on core patient-reported outcomes in cancer clinical trials: symptomatic adverse events, physical function, and disease-related symptoms","volume":"22","author":"Kluetz","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.euf.2019.02.020_bib0040","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s12955-016-0426-6","volume":"14","author":"Bennett","year":"2016","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.euf.2019.02.020_bib0045","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1200\/JCO.2017.75.2170","article-title":"Quality of life outcomes for cabozantinib versus everolimus in patients with metastatic renal cell carcinoma: METEOR phase III randomized trial","volume":"36","author":"Cella","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2019.02.020_bib0050","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S1470-2045(18)30778-2","article-title":"Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial","volume":"20","author":"Cella","year":"2019","journal-title":"Lancet Oncol"},{"issue":"suppl 6","key":"10.1016\/j.euf.2019.02.020_bib0055","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1200\/JCO.2018.36.6_suppl.578","article-title":"IMmotion151: a randomized phase III study of atezolizumab plus bevacizumab vs sunitinib in untreated metastatic renal cell carcinoma (mRCC)","volume":"36","author":"Motzer","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2019.02.020_bib0060","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.jval.2013.04.015","article-title":"Development and initial validation of the NCCN\/FACT symptom index for advanced kidney cancer","volume":"16","author":"Rothrock","year":"2013","journal-title":"Value Health"},{"key":"10.1016\/j.euf.2019.02.020_bib0065","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","article-title":"Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)","volume":"20","author":"Herdman","year":"2011","journal-title":"Qual Life Res"},{"key":"10.1016\/j.euf.2019.02.020_bib0070","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1002\/(SICI)1097-0142(19990301)85:5<1186::AID-CNCR24>3.0.CO;2-N","article-title":"The rapid assessment of fatigue severity in cancer patients: use of the Brief Fatigue Inventory","volume":"85","author":"Mendoza","year":"1999","journal-title":"Cancer"},{"key":"10.1016\/j.euf.2019.02.020_bib0075","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1002\/1097-0142(20001001)89:7<1634::AID-CNCR29>3.0.CO;2-V","article-title":"Assessing symptom distress in cancer patients: the M.D. Anderson Symptom Inventory","volume":"89","author":"Cleeland","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.euf.2019.02.020_bib0080","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1200\/JCO.2013.50.8267","article-title":"Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES study","volume":"32","author":"Escudier","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2019.02.020_bib0085","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/S0140-6736(17)33297-X","article-title":"Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial","volume":"391","author":"Powles","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.euf.2019.02.020_bib0090","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/S1470-2045(17)30616-2","article-title":"First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study","volume":"18","author":"Balar","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euf.2019.02.020_bib0095","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/S0090-4295(97)00459-7","article-title":"Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument","volume":"50","author":"Esper","year":"1997","journal-title":"Urology"},{"key":"10.1016\/j.euf.2019.02.020_bib0100","first-page":"129","article-title":"Pain assessment: global use of the Brief Pain Inventory","volume":"23","author":"Cleeland","year":"1994","journal-title":"Ann Acad Med Singapore"},{"key":"10.1016\/j.euf.2019.02.020_bib0105","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.eururo.2016.07.027","article-title":"Impact of enzalutamide compared with bicalutamide on quality of life in men with metastatic castration-resistant prostate cancer: additional analyses from the TERRAIN randomised clinical trial","volume":"71","author":"Heidenreich","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2019.02.020_bib0110","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/S1470-2045(17)30911-7","article-title":"Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial","volume":"19","author":"Chi","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euf.2019.02.020_bib0115","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/S1470-2045(18)30456-X","article-title":"Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial","volume":"19","author":"Saad","year":"2018","journal-title":"Lancet Oncol"},{"issue":"4s","key":"10.1016\/j.euf.2019.02.020_bib0120","doi-asserted-by":"crossref","first-page":"e703","DOI":"10.1016\/j.juro.2018.02.1670","article-title":"MP 52-19 impact of enzalutamide on pain and health-related quality of life in men with non-metastatic castration-resistant prostate cancer: PROSPER study results","volume":"199","author":"Saad","year":"2018","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2019.02.020_bib0125","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1200\/JCO.2017.75.3921","article-title":"Seven-month prostate-specific antigen is prognostic in metastatic hormone-sensitive prostate cancer treated with androgen deprivation with or without docetaxel","volume":"36","author":"Harshman","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2019.02.020_bib0130","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1702900","article-title":"Abiraterone for prostate cancer not previously treated with hormone therapy","volume":"377","author":"James","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euf.2019.02.020_bib0135","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","article-title":"EuroQol\u2014a new facility for the measurement of health-related quality of life","volume":"16","author":"EuroQol Group","year":"1990","journal-title":"Health Policy"},{"key":"10.1016\/j.euf.2019.02.020_bib0140","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.jclinepi.2010.04.011","article-title":"The Patient-Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005\u20132008","volume":"63","author":"Cella","year":"2010","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.euf.2019.02.020_bib0145","doi-asserted-by":"crossref","first-page":"190","DOI":"10.6004\/jnccn.2013.0027","article-title":"Distress management","volume":"11","author":"Holland","year":"2013","journal-title":"J Natl Compr Canc Network"},{"key":"10.1016\/j.euf.2019.02.020_bib0150","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1177\/082585979100700202","article-title":"The Edmonton Symptom Assessment System (ESAS): a simple method for the assessment of palliative care patients","volume":"7","author":"Bruera","year":"1991","journal-title":"J Palliat Care"},{"key":"10.1016\/j.euf.2019.02.020_bib0155","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1016\/0959-8049(94)90182-1","article-title":"The Memorial Symptom Assessment Scale: an instrument for the evaluation of symptom prevalence, characteristics and distress","volume":"30a","author":"Portenoy","year":"1994","journal-title":"Eur J Cancer"}],"container-title":["European Urology Focus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456919300550?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456919300550?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T06:50:29Z","timestamp":1762498229000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405456919300550"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S2405456919300550"],"URL":"https:\/\/doi.org\/10.1016\/j.euf.2019.02.020","relation":{},"ISSN":["2405-4569"],"issn-type":[{"type":"print","value":"2405-4569"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patient-reported Outcome Measures in Metastatic Urinary Cancers","name":"articletitle","label":"Article Title"},{"value":"European Urology Focus","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euf.2019.02.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}